← Back to Search

Detraining on Atrial Fibrillation (DAF Trial)

N/A
Waitlist Available
Led By James McKinney, MD
Research Sponsored by Cardiology Research UBC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up taken at 0, 8, and 32 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if reducing exercise for a few months can help athletes with a specific type of irregular heartbeat by using a device to monitor their heart rhythm. The goal is to see if this approach can prevent the irregular heartbeat from coming back and improve their quality of life.

Eligible Conditions
  • Atrial Fibrillation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~taken at 0, 8, and 32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and taken at 0, 8, and 32 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ratio of atrial fibrillation (AF) episodes
Symptomatic palpitations
Secondary study objectives
AF symptom severity
Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score
Electric Countershock
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Prescribed DetrainingExperimental Treatment1 Intervention
Detraining period of 8-weeks which is defined as: 1. a 75% decrease in the amount of exercise (from baseline) 2. a 50% decrease in the intensity of exercise as measured in METS (from baseline) 3. Mitchell Classification classes 1A, 2A, 2B of activity are permitted
Group II: Continued Strenuous ExerciseActive Control1 Intervention
Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period

Find a Location

Who is running the clinical trial?

Cardiology Research UBCLead Sponsor
15 Previous Clinical Trials
7,074 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
100 Patients Enrolled for Atrial Fibrillation
James McKinney, MDPrincipal InvestigatorUniversity of British Columbia Department of Medicine
~10 spots leftby Dec 2025